Amlenetug治疗多系统萎缩的AMULET二期试验

原文

BACKGROUND: Pathological aggregation and propagation of α-synuclein species drive disease progression in multiple system atrophy (MSA). We assessed the efficacy and safety of amlenetug, a monoclonal antibody targeting aggregated α‑synuclein, versus placebo in slowing clinical disease progression in people with MSA. METHODS: We did a randomised, controlled, parallel-group trial (AMULET) at 18 movement disorder and autonomic dysfunction specialist sites across the USA and Japan. Patients aged 40-75 years with MSA who had motor symptom onset in the past 5 years were randomly assigned (2:1) to intravenous amlenetug or placebo every 4 weeks for 48-72 weeks in a common close design. Randomisation was performed via an interactive response system, stratified by region and blood neurofilament light chain concentration, using a block size of three. The double-blind treatment period ended when the last randomised participant had concluded the week 48 visit. Participants, study partners, treating investigators, study site personnel, and the sponsor were masked to treatment allocation. The primary endpoint was disease progression, assessed using a Bayesian progression model of the longitudinal changes from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) total (parts I and II) score up to week 72, in all participants who had a valid baseline assessment and at least one valid post-baseline assessment of UMSARS total score. Safety was assessed in all treated participants. This trial is registered at ClinicalTrials.gov (NCT05104476); the open-label phase of the trial is ongoing. FINDINGS: Between Nov 16, 2021, and Oct 6, 2022, 91 unique participants were screened, of whom 64 were randomly assigned and 61 received treatment (amlenetug n=40; placebo n=21). Among treated participants, mean age was 60·8 years (SD 7·7); 32 (52%) were male and 29 (48%) female. 48 (79%) of 61 participants completed double-blind treatment (mean 56 weeks [SD 13] treatment). The Bayesian probability of 89·4% for a true slowing of clinical disease progression did not reach the predefined threshold of 97·5%, and accordingly, the primary endpoint was not met. The effect parameter of 0·81 (2·5th to 97·5th percentile 0·56 to 1·13) equates to a non-significant slowing of clinical progression by 19% (2·5th to 97·5th percentile -13 to 44) for amlenetug versus placebo. Amlenetug was generally well tolerated, with comparable rates of treatment‑emergent adverse events (n=40 [100%] with amlenetug vs n=20 [95%] with placebo) and serious treatment‑emergent adverse events (n=12 [30%] vs n=7 [33%]). The most common treatment-emergent adverse events were COVID‑19 infection (n=11 [28%] vs n=5 [24%]), back pain (n=6 [15%] vs n=2 [10%]), headache (n=5 [13%] vs n=1 [5%]), urinary tract infection (n=4 [10%] vs n=3 [14%]), peripheral oedema ([n=4] 10% vs n=1 [5%]), flushing (n=4 [10%] vs 0), and hypertension (n=4 [10%] vs 0). Two deaths occurred in each group, with only one death, in the placebo group, considered possibly treatment related. INTERPRETATION: Although the trial did not meet its primary endpoint, the statistically non-significant finding of potentially slowed clinical progression, together with an acceptable safety profile, supported further evaluation in a phase 3 trial. FUNDING: H Lundbeck.